不列颠哥伦比亚省温哥华 - 根据新闻稿声明,AbCellera Biologics Inc.(纳斯达克股票代码:ABCL)将在2026年5月11日的2026年第一季度财报电话会议上披露ABCL635的1期中期结果。该股在过去一年中飙升65.7%,目前交易价格为$4.01,市值为12.2亿美元。 该公司计划分享该研究1期部分的安全性概况、药代动力学和药效学靶点参与数据。ABCL635是一种靶向神经激 ...

Investing.com - Truist Securities在与公司高管进行讨论后,重申了对AbCellera Biologics(NASDAQ:ABCL)的买入评级和10.00美元的目标价。该目标价较当前3.85美元的股价具有显著上涨空间,但低于华尔街12美元的最高目标价。 该公司回顾了与AbCellera首席医疗官Sarah Noonberg博士和首席财务官Andrew Booth的讨论 ...

ABCL635 is a potential first-in-class antibody therapeutic targeting the neurokinin 3 receptor (NK3R) for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS) associated with ...

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best stocks under $5 with huge upside potential. On April 9, ...

Investors in AbCellera Biologics Inc (Symbol: ABCL) saw new options become available this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

In early April 2026, Jones Trading began covering AbCellera Biologics with a positive rating, highlighting the company’s antibody-based medicines platform and advancing clinical and discovery programs ...

AbCellera Biologics is a biotech company using AI-powered platforms to discover and analyze target-specific antibodies. The company emphasizes partnerships to expedite drug development and has two ...

We successfully completed the CPA process for ABCL-635 in 2025, and today, we are pleased to announce that we have begun dosing participants. The ABCL-635 Phase One clinical trial is a randomized, ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the most promising penny stocks under $5 to buy. On February 24, AbCellera Biologics announced its Q4 and full-year 2025 financial results, marking a ...